A good day for Oxigene (OXGN +18.5%), as shares soar on news that the biotech firm is again in...

|By:, SA News Editor

A good day for Oxigene (OXGN +18.5%), as shares soar on news that the biotech firm is again in compliance with Nasdaq minimum market and stock value requirements, and the company reports encouraging data on a phase 2 trial of its Zybrestat non-small cell lung cancer drug.